Story perspectives

Biotech Firms Grant Over 600,000 Stock Options to New Hires

1/8/2025

50 8

Summary

Story summary

Gossamer Bio awarded 225,000 stock options to three new employees as inducement awards under Nasdaq Rule 5635(c)(4).
Avadel Pharmaceuticals approved 131,700 options for twelve new hires, also under Nasdaq Rule 5635(c)(4).
Xeris Biopharma granted 181,500 restricted stock units to 19 new employees, vesting over three years.
Cartesian Therapeutics issued options for 19,324 shares to three new employees, vesting over four years.
Milestone Pharmaceuticals provided 113,000 options to three new hires, with a four-year vesting schedule.

History

Historical Context

Recent stock option grants by Gossamer Bio, Avadel Pharmaceuticals, and others reflect a trend established post-2005 SEC reforms. These changes aimed to enhance competition and transparency in securities markets, echoing earlier regulatory shifts in the 1970s that sought to unify fragmented trading platforms and improve investor protections.

1 of 2

Story summary

Gossamer Bio awarded 225,000 stock options to three new employees as inducement awards under Nasdaq Rule 5635(c)(4).
Avadel Pharmaceuticals approved 131,700 options for twelve new hires, also under Nasdaq Rule 5635(c)(4).
Xeris Biopharma granted 181,500 restricted stock units to 19 new employees, vesting over three years.
Cartesian Therapeutics issued options for 19,324 shares to three new employees, vesting over four years.
Milestone Pharmaceuticals provided 113,000 options to three new hires, with a four-year vesting schedule.

1 / 2